1
|
Atre T, Nguyen V, Chow V, Reid GSD, Vercauteren S. A Comparative Study of B Cell Blast Isolation Methods from Bone Marrow Aspirates of Pediatric Leukemia Patients. Biopreserv Biobank 2024. [PMID: 38686645 DOI: 10.1089/bio.2023.0133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2024] Open
Abstract
Density gradient centrifugation is a conventional technique widely utilized to isolate bone marrow mononuclear cells (BM-MNC) from bone marrow (BM) aspirates obtained from pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients. Nevertheless, this technique achieves incomplete recovery of mononuclear cells and is relatively time-consuming and expensive. Given that B-ALL is the most common childhood malignancy, alternative methods for processing B-ALL samples may be more cost-effective. In this pilot study, we use several readouts, including immune phenotype, cell viability, and leukemia-initiating capacity in immune-deficient mice, to directly compare the density gradient centrifugation and buffy coat processing methods. Our findings indicate that buffy coat isolation yields comparable BM-MNC product in terms of both immune and leukemia cell content and could provide a viable, lower cost alternative for biobanks processing pediatric leukemia samples.
Collapse
Affiliation(s)
- Tanmaya Atre
- Michael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, Canada
| | - Vi Nguyen
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
- BC Children's Hospital BioBank, BC Children's Hospital, Vancouver, Canada
| | - Veronica Chow
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
- BC Children's Hospital BioBank, BC Children's Hospital, Vancouver, Canada
| | - Gregor S D Reid
- Michael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, Canada
- Department of Pediatrics, University of British Columbia, Vancouver, Canada
| | - Suzanne Vercauteren
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
- BC Children's Hospital BioBank, BC Children's Hospital, Vancouver, Canada
- Department of Pediatrics, University of British Columbia, Vancouver, Canada
- Division of Hematopathology, BC Children's Hospital, Vancouver, Canada
| |
Collapse
|
2
|
Slušná ĽK, Balog M. Review of Indicators in the Context of Biobanking. Biopreserv Biobank 2023; 21:318-326. [PMID: 36099204 DOI: 10.1089/bio.2022.0073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background: Biobanks that intend to serve as high-performing and stable elements of an innovative research ecosystem must have an established system for regular measurement and evaluation using appropriately set indicators. The main objective of this study was to provide a comprehensive overview of indicators in the context of biobanking, with new perspectives to highlight the existence of numerous options and introduce indicators that could help overcome problems associated with the difficult assessment of the impact of biobanks. Methods: A literature review was performed to identify publications relevant to the topic of indicators in biobanking. The Web of Science Core Collection and PubMed databases were searched using specific keywords. In addition, three articles that focused on indicators designed for the evaluation of research infrastructures were included in the review. Results: Based on the scientific literature for the biobanking field, many types of quantitative and qualitative indicators exist. They are mainly related to the quantity and quality of data and samples, their distribution, the monitoring of research projects, and subsequent publication outputs. The indicators identified in the biobanking literature primarily focus on the outcome, not the impact. Conclusions: Indicators identified in the biobanking literature may be further expanded with suggestions designed for other types of research infrastructures, while considering the context where biobanks operate and the needs of individual biobanking stakeholders. The establishment of a comprehensive monitoring system that captures all necessary elements is crucial for modern biobanks.
Collapse
Affiliation(s)
| | - Miroslav Balog
- Centre of Social and Psychological Sciences, SAS, Bratislava, Slovakia
| |
Collapse
|
3
|
D’Vaz N, Kidd C, Miller S, Amin M, Davis JA, Talati Z, Silva DT, Prescott SL. The ORIGINS Project Biobank: A Collaborative Bio Resource for Investigating the Developmental Origins of Health and Disease. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2023; 20:6297. [PMID: 37444144 PMCID: PMC10341236 DOI: 10.3390/ijerph20136297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 06/27/2023] [Accepted: 06/27/2023] [Indexed: 07/15/2023]
Abstract
Early onset Non-Communicable Diseases (NCDs), including obesity, allergies, and mental ill-health in childhood, present a serious and increasing threat to lifelong health and longevity. The ORGINS Project (ORIGINS) addresses the urgent need for multidisciplinary efforts to understand the detrimental multisystem impacts of modern environments using well-curated large-scale longitudinal biological sample collections. ORGINS is a prospective community birth cohort aiming to enrol 10,000 pregnant people and follow each family until the children reach 5 years of age. A key objective is to generate a comprehensive biorepository on a sub-group of 4000 families invited to contribute blood, saliva, buccal cells, urine, stool, hair, house dust, cord blood, placenta, amniotic fluid, meconium, breastmilk, and colostrum over eight timepoints spanning the antenatal period and early childhood. Uniquely, ORIGINS includes a series of nested sub-projects, including interventions and clinical trials addressing different aspects of health. While this adds complexity as the project expands, it provides the opportunity for comparative studies. This research design promotes a multidisciplinary, multisystem approach to biological sample collection, analysis, and data sharing to ensure more integrated perspectives and solutions. This paper details the evolving protocol of our collaborative biobanking concept. Further, we outline our future visions for local, national, and ultimately international, comparative, and collaborative opportunities to advance our understanding of early onset NCDs and the opportunities to improve health outcomes for future generations.
Collapse
Affiliation(s)
- Nina D’Vaz
- Telethon Kids Institute, North Entrance Perth Children’s Hospital, 15 Hospital Ave, Nedlands, WA 6009, Australia; (C.K.); (S.M.); (M.A.); (J.A.D.); (Z.T.); (D.T.S.); (S.L.P.)
- School of Medical and Health Sciences, Edith Cowan University, Perth, WA 6027, Australia
| | - Courtney Kidd
- Telethon Kids Institute, North Entrance Perth Children’s Hospital, 15 Hospital Ave, Nedlands, WA 6009, Australia; (C.K.); (S.M.); (M.A.); (J.A.D.); (Z.T.); (D.T.S.); (S.L.P.)
| | - Sarah Miller
- Telethon Kids Institute, North Entrance Perth Children’s Hospital, 15 Hospital Ave, Nedlands, WA 6009, Australia; (C.K.); (S.M.); (M.A.); (J.A.D.); (Z.T.); (D.T.S.); (S.L.P.)
| | - Minda Amin
- Telethon Kids Institute, North Entrance Perth Children’s Hospital, 15 Hospital Ave, Nedlands, WA 6009, Australia; (C.K.); (S.M.); (M.A.); (J.A.D.); (Z.T.); (D.T.S.); (S.L.P.)
| | - Jacqueline A. Davis
- Telethon Kids Institute, North Entrance Perth Children’s Hospital, 15 Hospital Ave, Nedlands, WA 6009, Australia; (C.K.); (S.M.); (M.A.); (J.A.D.); (Z.T.); (D.T.S.); (S.L.P.)
- School of Medical and Health Sciences, Edith Cowan University, Perth, WA 6027, Australia
- School of Population Health, Faculty of Health Sciences, Curtin University, Perth, WA 6102, Australia
| | - Zenobia Talati
- Telethon Kids Institute, North Entrance Perth Children’s Hospital, 15 Hospital Ave, Nedlands, WA 6009, Australia; (C.K.); (S.M.); (M.A.); (J.A.D.); (Z.T.); (D.T.S.); (S.L.P.)
| | - Desiree T. Silva
- Telethon Kids Institute, North Entrance Perth Children’s Hospital, 15 Hospital Ave, Nedlands, WA 6009, Australia; (C.K.); (S.M.); (M.A.); (J.A.D.); (Z.T.); (D.T.S.); (S.L.P.)
- School of Medical and Health Sciences, Edith Cowan University, Perth, WA 6027, Australia
- School of Population Health, Faculty of Health Sciences, Curtin University, Perth, WA 6102, Australia
- Department of Paediatrics and Neonatology, Joondalup Health Campus, Perth, WA 6027, Australia
- Medical School, University of Western Australia, Nedlands, WA 6009, Australia
| | - Susan L. Prescott
- Telethon Kids Institute, North Entrance Perth Children’s Hospital, 15 Hospital Ave, Nedlands, WA 6009, Australia; (C.K.); (S.M.); (M.A.); (J.A.D.); (Z.T.); (D.T.S.); (S.L.P.)
- School of Medical and Health Sciences, Edith Cowan University, Perth, WA 6027, Australia
- Medical School, University of Western Australia, Nedlands, WA 6009, Australia
- Scholars Program, Nova Institute for Health, Baltimore, MD 21231, USA
- Department of Immunology, Perth Children’s Hospital, Nedlands, WA 6009, Australia
| |
Collapse
|
4
|
Economics of Biobanking: Business or Public Good? Literature Review, Structural and Thematic Analysis. SOCIAL SCIENCES-BASEL 2022. [DOI: 10.3390/socsci11070288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
This paper reviewed the relevant scientific literature on the business and economics of biobanking to explore key themes and paradigms. The structural properties of the literature were investigated, such as key authors, journals, studies, as well as co-citation and co-authorship networks; the study revealed that the research on business and economics is a niche area within the vast biobanking literature. The research is concentrated in a relatively small number of journals, institutions, and countries, which is rather surprising given the substantial public investment in and concerns about biobank sustainability. The structural analysis also suggested major themes in research on biobanking business and economics and noted shifts in focus on specific themes. The commercialisation of samples is more acknowledged than before but under the condition of equitable sharing of benefits across various stakeholders. Most biobanks are heavily subsidised by the public sector and are considered public goods rather than business enterprises. This is OK, but underutilisation of specimens and low rates of cost recovery suggest that the current mainstream operating model is hardly sustainable. With many biobanks maturing, long-term sustainability became a key topic of the discussion on biobanking trends.
Collapse
|
5
|
Nguyen CQ, Alba-Concepcion K, Palmer EE, Scully JL, Millis N, Farrar MA. The involvement of rare disease patient organisations in therapeutic innovation across rare paediatric neurological conditions: a narrative review. Orphanet J Rare Dis 2022; 17:167. [PMID: 35436886 PMCID: PMC9014615 DOI: 10.1186/s13023-022-02317-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2021] [Accepted: 03/22/2022] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
The patient voice is becoming increasingly prominent across all stages of therapeutic innovation. It pervades research domains from funding and recruitment, to translation, care, and support. Advances in genomic technologies have facilitated novel breakthrough therapies, whose global developments, regulatory approvals, and confined governmental subsidisations have stimulated renewed hope amongst rare disease patient organisations (RDPOs). With intensifying optimism characterising the therapeutic landscape, researcher-advocate partnerships have reached an inflexion point, at which stakeholders may evaluate their achievements and formulate frameworks for future refinement.
Main text
Through this narrative review, we surveyed relevant literature around the roles of RDPOs catering to the rare paediatric neurological disease community. Via available literature, we considered RDPO interactions within seven domains of therapeutic development: research grant funding, industry sponsorship, study recruitment, clinical care and support, patient-reported outcome measures, and research prioritisation. In doing so, we explored practical and ethical challenges, gaps in understanding, and future directions of inquiry. Current literature highlights the increasing significance of ethical and financial challenges to patient advocacy. Biomedical venture philanthropy is gaining momentum amongst RDPOs, whose small grants can incrementally assist laboratories in research, training, and pursuits of more substantial grants. However, RDPO seed funding may encounter long-term sustainability issues and difficulties in selecting appropriate research investments. Further challenges include advocate-industry collaborations, commercial biases, and unresolved controversies regarding orphan drug subsidisation. Beyond their financial interactions, RDPOs serve instrumental roles in project promotion, participant recruitment, biobank creation, and patient registry establishment. They are communication conduits between carers, patients, and other stakeholders, but their contributions may be susceptible to bias and unrealistic expectations.
Conclusion
Further insights into how RDPOs navigate practical and ethical challenges in therapeutic development may enhance cooperative efforts. They may also inform resources, whose distribution among advocates, parents, and clinicians, may assist decision-making processes around rare disease clinical trials and treatments.
Collapse
|
6
|
Akyüz K, Chassang G, Goisauf M, Kozera Ł, Mezinska S, Tzortzatou O, Mayrhofer MT. Biobanking and risk assessment: a comprehensive typology of risks for an adaptive risk governance. LIFE SCIENCES, SOCIETY AND POLICY 2021; 17:10. [PMID: 34903285 PMCID: PMC8666836 DOI: 10.1186/s40504-021-00117-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Accepted: 12/01/2021] [Indexed: 05/03/2023]
Abstract
Biobanks act as the custodians for the access to and responsible use of human biological samples and related data that have been generously donated by individuals to serve the public interest and scientific advances in the health research realm. Risk assessment has become a daily practice for biobanks and has been discussed from different perspectives. This paper aims to provide a literature review on risk assessment in order to put together a comprehensive typology of diverse risks biobanks could potentially face. Methodologically set as a typology, the conceptual approach used in this paper is based on the interdisciplinary analysis of scientific literature, the relevant ethical and legal instruments and practices in biobanking to identify how risks are assessed, considered and mitigated. Through an interdisciplinary mapping exercise, we have produced a typology of potential risks in biobanking, taking into consideration the perspectives of different stakeholders, such as institutional actors and publics, including participants and representative organizations. With this approach, we have identified the following risk types: economic, infrastructural, institutional, research community risks and participant's risks. The paper concludes by highlighting the necessity of an adaptive risk governance as an integral part of good governance in biobanking. In this regard, it contributes to sustainability in biobanking by assisting in the design of relevant risk management practices, where they are not already in place or require an update. The typology is intended to be useful from the early stages of establishing such a complex and multileveled biomedical infrastructure as well as to provide a catalogue of risks for improving the risk management practices already in place.
Collapse
Affiliation(s)
- Kaya Akyüz
- BBMRI-ERIC, Graz, Austria.
- Department of Science and Technology Studies, University of Vienna, Vienna, Austria.
| | - Gauthier Chassang
- BBMRI-ERIC, Graz, Austria
- CERPOP, Université de Toulouse, Inserm, Université Paul Sabatier, Toulouse, France
| | - Melanie Goisauf
- BBMRI-ERIC, Graz, Austria
- Department of Science and Technology Studies, University of Vienna, Vienna, Austria
| | | | - Signe Mezinska
- BBMRI-ERIC, Graz, Austria
- Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia
| | - Olga Tzortzatou
- BBMRI-ERIC, Graz, Austria
- Biomedical Research Foundation of the Academy of Athens, Athens, Greece
| | | |
Collapse
|
7
|
van der Stijl R, Manders P, Eijdems EWHM. Recommendations for a Dutch Sustainable Biobanking Environment. Biopreserv Biobank 2021; 19:228-240. [PMID: 34042498 PMCID: PMC8217590 DOI: 10.1089/bio.2021.0011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Biobanks and their collections are considered essential for contemporary biomedical research and a critical resource toward personalized medicine. However, they need to operate in a sustainable manner to prevent research waste and maximize impact. Sustainability is the capacity of a biobank to remain operative, effective, and competitive over its expected lifetime. This remains a challenge given a biobank's position at the interplay of ethical, societal, scientific, and commercial values and the difficulties in finding continuous funding. In the end, biobanks are responsible for their own sustainability. Still, biobanks also depend on their surrounding environment, which contains overarching legislative, policy, financial, and other factors that can either impede or promote sustainability. The Biobanking and Biomolecular Research Infrastructure for The Netherlands (BBMRI.nl) has worked on improving the national environment for sustainable biobanking. In this article, we present the final outcomes of this BBMRI.nl project. First, we summarize the current overarching challenges of the Dutch biobanking landscape. These challenges were gathered during workshops and focus groups with Dutch biobanks and their users, for which the full results are described in separate reports. The main overarching challenges relate to sample and data quality, funding, use and reuse, findability and accessibility, and the general image of biobanks. Second, we propose a package of recommendations—across nine themes—toward creating overarching conditions that stimulate and enable sustainable biobanking. These recommendations serve as a guideline for the Dutch biobanking community and their stakeholders to jointly work toward practical implementation and a better biobanking environment. There are undoubtedly parallels between the Dutch situation and the challenges found in other countries. We hope that sharing our project's approach, outcomes, and recommendations will support other countries in their efforts toward sustainable biobanking.
Collapse
Affiliation(s)
- Rogier van der Stijl
- University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.,UMCG Research BV, University Medical Center Groningen, Groningen, The Netherlands.,BBMRI.nl, Biobanking and Biomolecular Resources Research Infrastructure, The Netherlands
| | - Peggy Manders
- Radboud Biobank, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Elisabeth W H M Eijdems
- University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.,BBMRI.nl, Biobanking and Biomolecular Resources Research Infrastructure, The Netherlands
| |
Collapse
|
8
|
Lin RC, Sacher JC, Ceyssens PJ, Zheng J, Khalid A, Iredell JR. Phage Biobank: Present Challenges and Future Perspectives. Curr Opin Biotechnol 2021; 68:221-230. [PMID: 33581425 DOI: 10.1016/j.copbio.2020.12.018] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2020] [Revised: 12/14/2020] [Accepted: 12/23/2020] [Indexed: 11/24/2022]
Abstract
After a century of use in human infection, the preparation and administration of therapeutic bacteriophages (phages) still relies on ad hoc partnerships of researchers, biotech companies, clinicians and regulators. There is a clear need to improve the reproducibility, safety and speed of the provision of suitable phages. Here we discuss the specific characteristics and challenges of a sustainable phage biobank and, as we build a national consortium aimed at delivering phage therapeutics, suggest a roadmap toward national biobanking and phage therapy initiatives using the Australian context as a model.
Collapse
Affiliation(s)
- Ruby Cy Lin
- Centre for Infectious Diseases and Microbiology, Westmead Institute for Medical Research, Sydney, Australia; Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, Australia; School of Medical Sciences, University of New South Wales, Sydney, Australia.
| | | | - Pieter-Jan Ceyssens
- Antibiotics and Resistance Unit, The National Reference Centres for Salmonella, Shigella, Listeria, Neisseria and Mycobacteria, Sciensano, Belgium
| | - Jan Zheng
- Phage Directory, Atlanta, Georgia, USA.
| | - Ali Khalid
- Centre for Infectious Diseases and Microbiology, Westmead Institute for Medical Research, Sydney, Australia; Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, Australia
| | - Jonathan R Iredell
- Centre for Infectious Diseases and Microbiology, Westmead Institute for Medical Research, Sydney, Australia; Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, Australia; Westmead Hospital, Western Sydney Local Health District, Sydney, Australia.
| | | |
Collapse
|
9
|
Rush A, Catchpoole DR, Ling R, Searles A, Watson PH, Byrne JA. Improving Academic Biobank Value and Sustainability Through an Outputs Focus. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2020; 23:1072-1078. [PMID: 32828220 DOI: 10.1016/j.jval.2020.05.010] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/14/2020] [Revised: 05/18/2020] [Accepted: 05/23/2020] [Indexed: 06/11/2023]
Abstract
Although it is generally accepted that human tissue biobanks are important to facilitate progress in health and medical research, many academic biobanks face sustainability challenges. We propose that biobank sustainability is challenged by a lack of available data describing the outputs and benefits that are produced by biobanks, as reflected by a dearth of publications that enumerate biobank outputs. We further propose that boosting the available information on biobank outputs and using a broader range of output metrics will permit economic analyses such as cost-consequence analyses of biobank activity. Output metrics and cost-consequence analyses can allow biobanks to achieve efficiencies, and improve the quality and/or quantity of their outputs. In turn, biobank output measures provide all stakeholders with explicit and accountable data on biobank value, which could contribute to the evolution of biobank operations to best match research needs, and mitigate some threats to biobank sustainability.
Collapse
Affiliation(s)
- Amanda Rush
- Discipline of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
| | - Daniel R Catchpoole
- Children's Cancer Research Unit, Kids Research, The Children's Hospital at Westmead, Westmead, NSW, Australia
| | - Rod Ling
- Health Research Economics, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia
| | - Andrew Searles
- Health Research Economics, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia
| | - Peter H Watson
- Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
| | - Jennifer A Byrne
- NSW Health Statewide Biobank, NSW Health Pathology, Professor Marie Bashir Centre, Camperdown, NSW, Australia.
| |
Collapse
|
10
|
Osman I, Cotzia P, Moran U, Donnelly D, Arguelles-Grande C, Mendoza S, Moreira A. The urgency of utilizing COVID-19 biospecimens for research in the heart of the global pandemic. J Transl Med 2020; 18:219. [PMID: 32487093 PMCID: PMC7266426 DOI: 10.1186/s12967-020-02388-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2020] [Accepted: 05/22/2020] [Indexed: 02/04/2023] Open
Abstract
The outbreak of the novel coronavirus disease 2019 (COVID-19) and consequent social distancing practices have disrupted essential clinical research functions worldwide. Ironically, this coincides with an immediate need for research to comprehend the biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the pathology of COVID-19. As the global crisis has already led to over 15,000 deaths out of 175,000 confirmed cases in New York City and Nassau County, NY alone, it is increasingly urgent to collect patient biospecimens linked to active clinical follow up. However, building a COVID-19 biorepository amidst the active pandemic is a complex and delicate task. To help facilitate rapid, robust, and regulated research on this novel virus, we report on the successful model implemented by New York University Langone Health (NYULH) within days of outbreak in the most challenging hot spot of infection globally. Using an amended institutional biobanking protocol, these efforts led to accrual of 11,120 patients presenting for SARS-CoV-2 testing, 4267 (38.4%) of whom tested positive for COVID-19. The recently reported genomic characterization of SARS-CoV-2 in the New York City Region, which is a crucial development in tracing sources of infection and asymptomatic spread of the novel virus, is the first outcome of this effort. While this growing resource actively supports studies of the New York outbreak in real time, a worldwide effort is necessary to build a collective arsenal of research tools to deal with the global crisis now, and to exploit the virus's biology for translational innovation that outlasts humanity's current dilemma.
Collapse
Affiliation(s)
- Iman Osman
- The New York University Langone Health (NYULH) Center of Biospecimen Research and Development, Office of Science and Research, NYU Grossman School of Medicine, 522 First Avenue, SML405, New York, NY, 10016, USA.
| | - Paolo Cotzia
- The New York University Langone Health (NYULH) Center of Biospecimen Research and Development, Office of Science and Research, NYU Grossman School of Medicine, 522 First Avenue, SML405, New York, NY, 10016, USA
| | - Una Moran
- The New York University Langone Health (NYULH) Center of Biospecimen Research and Development, Office of Science and Research, NYU Grossman School of Medicine, 522 First Avenue, SML405, New York, NY, 10016, USA
| | - Douglas Donnelly
- The New York University Langone Health (NYULH) Center of Biospecimen Research and Development, Office of Science and Research, NYU Grossman School of Medicine, 522 First Avenue, SML405, New York, NY, 10016, USA
| | - Carolina Arguelles-Grande
- The New York University Langone Health (NYULH) Center of Biospecimen Research and Development, Office of Science and Research, NYU Grossman School of Medicine, 522 First Avenue, SML405, New York, NY, 10016, USA
| | - Sandra Mendoza
- The New York University Langone Health (NYULH) Center of Biospecimen Research and Development, Office of Science and Research, NYU Grossman School of Medicine, 522 First Avenue, SML405, New York, NY, 10016, USA
| | - Andre Moreira
- The New York University Langone Health (NYULH) Center of Biospecimen Research and Development, Office of Science and Research, NYU Grossman School of Medicine, 522 First Avenue, SML405, New York, NY, 10016, USA
| |
Collapse
|
11
|
Fernández IC, Merino IG, Muñoz-Fernández MÁ. Assessing and measuring financial sustainability model of the Spanish HIV HGM BioBank. J Transl Med 2020; 18:6. [PMID: 31907070 PMCID: PMC6943905 DOI: 10.1186/s12967-019-02187-w] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Accepted: 12/23/2019] [Indexed: 12/20/2022] Open
Abstract
Background The Spanish HIV HGM BioBank is of great relevance for basic and clinical investigation, and for those groups trying to establish large networks focused on investigation on specific clinical problems. The collection of different types of samples from HIV-infected individuals is the beginning of the chain of translational investigation, starting in 2004 a prospective national HIV BioBank that expanded in 2009 a local node (HGM: Hospital Gregorio Marañón) for diverse pathologies and clinical networks, not only in adults but also in paediatric patients, becoming the Spanish HIV HGM BioBank. Our main objective is to find a general criteria and analytical tools to widespread its economic management to assure their sustainability and the future exploitation of the extreme high valuable biomaterial they custody. Methods The Spanish HIV HGM BioBank was created with the aim of contributing to advance understanding of different pathologies through the transfer, management, register, processing, cryopreservation and cession of biological material from patients, always for research purposes and under conditions that guarantee its usefulness in current studies and future research that may appear as knowledge evolves. In this study, we have developed a policy for financial control and recovery costs of the Spanish HIV HGM BioBank. Results Actually, Spanish HIV HGM BioBank guards 413,747 vials of 46,594 samples from 16,210 donors with various prospective longitudinal study type of samples. Interestingly, more than 7907 of these samples are now used in 28 national and international investigation projects and clinical trials. One of the objectives of this study is to develop an economic plan that you get future projects, design of acceptance or rejection keys, have internal investment limits, minimum recovery needs in short/medium term, deviation detection system and a register of capital recovery by period and type of service for the Spanish HIV HGM BioBank. Conclusion Our model can help BioBanks that do not have a costs recovery model to design it, as well as to detect improves and functional revisions to those experienced in this field.
Collapse
Affiliation(s)
- Irene Consuegra Fernández
- Immunology Section, Molecular ImmunoBiology Laboratory, Hospital General Universitario Gregorio Marañón and Instituto Investigación Sanitaria Gregorio Marañón, C/Doctor Esquerdo 46, 28007, Madrid, Spain.,Spanish HIV HGM BioBank, Madrid, Spain.,Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, 28029, Madrid, Spain
| | - Isabel García Merino
- Immunology Section, Molecular ImmunoBiology Laboratory, Hospital General Universitario Gregorio Marañón and Instituto Investigación Sanitaria Gregorio Marañón, C/Doctor Esquerdo 46, 28007, Madrid, Spain.,Spanish HIV HGM BioBank, Madrid, Spain.,Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, 28029, Madrid, Spain
| | - María Ángeles Muñoz-Fernández
- Immunology Section, Molecular ImmunoBiology Laboratory, Hospital General Universitario Gregorio Marañón and Instituto Investigación Sanitaria Gregorio Marañón, C/Doctor Esquerdo 46, 28007, Madrid, Spain. .,Spanish HIV HGM BioBank, Madrid, Spain. .,Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, 28029, Madrid, Spain.
| |
Collapse
|
12
|
Yang F, Wang S, Guo J, Liu X, Ge N, Wang G, Sun S. EUS-guided fine-needle technique facilitates the establishment of organoid biobanks. Endosc Ultrasound 2020; 9:355-360. [PMID: 33318374 PMCID: PMC7811707 DOI: 10.4103/eus.eus_79_20] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Affiliation(s)
- Fan Yang
- Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China
| | - Sheng Wang
- Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China
| | - Jintao Guo
- Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China
| | - Xiang Liu
- Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China
| | - Nan Ge
- Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China
| | - Guoxin Wang
- Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China
| | - Siyu Sun
- Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China
| |
Collapse
|
13
|
Church TD, Richmond FJ. Biobank Continuity Management: A Survey of Biobank Professionals. Biopreserv Biobank 2019; 17:410-417. [PMID: 31017454 DOI: 10.1089/bio.2018.0142] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Academic biobanks face challenges that call for continuity and disaster planning. However, current regulations do not require such planning, so it is unclear if and how biobanks have prepared themselves to deal with future crises. This exploratory study used mixed methods to understand the state of continuity planning in U.S. biobanks. It first reviewed the current state of regulatory and implementation requirements that drive and challenge continuity planning. A survey instrument was then developed and critiqued by a focus group of experienced practitioners in biobanking. The refined survey was disseminated to a targeted group of respondents employed at biobanks across the United States. Most respondents were associated with relatively mature biobanks in operation for more than 6 years and these typically had some form of continuity plan in place. More commonly, continuity planning was reported to be focused on countering natural disasters rather than organization- or personnel-related crises. Respondents identified their most common limitation to be financial resources affecting all phases of implementation. Although many respondents appeared to be aware of some guidance documents and standards for continuity planning, many reported that they did not use or reference them when constructing their biobank continuity plans. Furthermore, nearly 25% of surveyed biobanks did not have a continuity plan and 61% indicated concern in having a mandated continuity plan. Results suggested academic organizations would benefit from a continuity plan template and best practice guidelines for plan development and implementation.
Collapse
Affiliation(s)
- Terry David Church
- Regulatory and Quality Sciences, University of Southern California (USC), USC School of Pharmacy, Los Angeles, California
| | - Frances J Richmond
- Regulatory and Quality Sciences, University of Southern California (USC), USC School of Pharmacy, Los Angeles, California
| |
Collapse
|
14
|
Patil S, Majumdar B, Awan KH, Sarode GS, Sarode SC, Gadbail AR, Gondivkar S. Cancer oriented biobanks: A comprehensive review. Oncol Rev 2018; 12:357. [PMID: 30057691 PMCID: PMC6047884 DOI: 10.4081/oncol.2018.357] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2018] [Accepted: 04/11/2018] [Indexed: 01/12/2023] Open
Abstract
Biobanks provide a platform for innovative biomedical research and has improvised translational and personalized medicine to a great extent. Time 2009 published 10 ideas changing the world right now with biobanks on the list emphasizing its role in discovery and development of new therapeutic drugs. They form the cornerstone, providing resources for future investigations and biomarker discovery to understand the effects of genetic, environmental and lifestyle factors on human morbidity, mortality and health. The aim of this review paper is to understand the role of biobanking in cancer research, the challenges faced and strategies to overcome these, for long term and sustainable research in the field of oncology.
Collapse
Affiliation(s)
- Shankargouda Patil
- Department of Oral and Maxillofacial Surgery and Diagnostic Sciences, Division of Oral Pathology, College of Dentistry, Jazan University, Jazan, Saudi Arabia
| | - Barnali Majumdar
- Department of Oral Pathology and Microbiology, Bhojia Dental College & Hospital, Baddi, Himachal Pradesh, India
| | - Kamran Habib Awan
- College of Dental Medicine, Roseman University of Health Sciences, South Jordan, UT, USA
| | - Gargi S Sarode
- Department of Oral Pathology and Microbiology, Dr. D. Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Maharashtra, India
| | - Sachin C Sarode
- Department of Oral Pathology and Microbiology, Dr. D. Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Maharashtra, India
| | - Amol R Gadbail
- Department of Dentistry, Indira Gandhi Government Medical College, Nagpur, Maharashtra, India
| | - Shailesh Gondivkar
- Department of Oral Medicine and Radiology, Government Dental College & Hospital, Nagpur, Maharashtra, India
| |
Collapse
|
15
|
Macheiner T, Huppertz B, Bayer M, Sargsyan K. Challenges and Driving Forces for Business Plans in Biobanking. Biopreserv Biobank 2017; 15:121-125. [PMID: 28338345 DOI: 10.1089/bio.2017.0018] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Due to increased utilization of biospecimens for research and emergence of new technologies, the availability and quality of biospecimens and their collection are coming more and more into focus. However, the long-term economic situation of biobanks is still mostly unclear. Also, the common sustainable utilization of various international biobanks is challenging due to local differences in sample processing, law and ethics. AIM This article discusses possible strategies to achieve a sustainable utilization of biospecimens as part of the business plan of biobanks. METHODS The following questions were addressed as part of a business plan: (1) How can a biobank build up and maintain an up-to-date infrastructure? (2) What kind of funding can support the sustainability of a biobank? (3) Is there an international solution for informed consents to enable sample and data sharing? (4) How can a biobank react during economically unstable periods? (5) Which kind of biobanking research is innovative? (6) What kind of education could be most needful for knowledge transfer in biobanking? (7) Does an expiration date for a biobank make sense according to the period of funding? CONCLUSION A strategy for optimal utilization begins with sharing of resources, infrastructure, and investments at the planning stage of a biobank, and continues to the transfer of knowledge and know-how by education. For clinical biobanks in particular, a long-term funding and cost recovery strategy is necessary for sustainable utilization.
Collapse
|
16
|
McCluskey K. A Review of Living Collections with Special Emphasis on Sustainability and Its Impact on Research Across Multiple Disciplines. Biopreserv Biobank 2016; 15:20-30. [PMID: 27869477 PMCID: PMC5327032 DOI: 10.1089/bio.2016.0066] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Formal living collections have unique characteristics that distinguish them from other types of biorepositories. Comprising diverse resources, microbe culture collections, crop and biodiversity plant germplasm collections, and animal germplasm repositories are commonly allied with specific research communities or stakeholder groups. Among living collections, microbial culture collections have very long and unique life histories, with some being older than 100 years. Regulatory, financial, and technical developments have impacted living collections in many ways. International treaty obligations and restrictions on release of genetically modified organisms complicate the activities of living collections. Funding for living collections is a continuing challenge and threatens to create a two-tier system where medically relevant collections are well funded and all other collections are underfunded and hence understaffed. Molecular, genetic, and whole genome sequence analysis of contents of microbes and other living resource collections bring additional value to living collections.
Collapse
Affiliation(s)
- Kevin McCluskey
- Fungal Genetics Stock Center, Department of Plant Pathology, Kansas State University , Manhattan, Kansas
| |
Collapse
|